Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma

European Journal of Haematology

Volumn 65, Issue 3, 2000, Pages 195-202

  Sasaki, Kyoko ^a   Niitsu, Nozomi ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

International Prognostic Index; Non Hodgkin's lymphoma; Prognostic factor; Soluble CD44 v6

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HERMES ANTIGEN; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; PREDNISOLONE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTASIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; T CELL LYMPHOMA;

ANTIGENS, CD44; FEMALE; HODGKIN DISEASE; HUMANS; L-LACTATE DEHYDROGENASE; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; RISK FACTORS; SOLUBILITY; SURVIVAL RATE; VARIATION (GENETICS);

EID: 0033856763     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.065003195.x     Document Type: Article

References (40)

1. CD44 contributes to T cell activation
2. Dual role of the CD44 molecule in T cell adhesion and activation
3. CD44 is the principal cell surface receptor for hyaluronate
4. Genomic structure of DNA encoding the lymphocyte horming receptor CD44 reveals at least 12 alternatively spliced exons
5. The multispecific cell adhesion molecule CD44 is represented in reticulocyte cDNA
6. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells
7. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression
8. Expression of CD44 and its clinical implication in diffuse-type and intestinal-type gastiric adenocarcinomas
9. CD44 variant isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor
10. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric and colon cancer
11. Serum CD44 in malignant lymphoma: An association with treatment response
12. A predictive model for aggressive non-Hodgkin's lymphomas. The International Non-Hodgkin's Lymphoma Prognostic Factors Project
13. Lymphoma classification: The gap between biology and clinical management is closing
14. Report of the Committee on Hodgkin's Disease Staging Classification
15. COP-BLAM regimen combined with granulocyte colony-stimulating factor (G-CSF) and high-grade non-Hodgkin's lymphoma
16. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkin's lymphoma
17. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma
18. Nonparametric estimation from incomplete observations
19. Individual comparisons by ranking methods
20. Evaluation of survival data and two new rank order statistics arising in its consideration
21. Regression models and life tables
22. Regulation of lymphocyte traffic to mucosa-associated lymphatic tissues
23. Regulated expression and binding of three VLA (β1) integrin receptors on T cells
24. CD44 splice variants: Metastases meet lymphocytes
25. Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma
26. Expression of lymphocyte horming receptor as a mechanism of dissemination in non-Hodgkin's lymphoma
27. Actived human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44
28. A strong expression of CD44-v6 correlates with shorter survival of patients with acute myeloid leukemia
29. Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis
30. Characterization of soluble CD44 in the circulation of mice. Levels are affected by immune activation and tumor growth
31. Clinical significance of circulation CD44 in non-Hodgkin's lymphoma
32. Increased serum levels of soluble CD44 standard, but not variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia
33. Serum soluble CD44 levels for monitoring disease states in acute leukemia and myelodysplastic syndromes
34. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer
35. Rising serum lactate dehydrogenase often caused by granulocyte-or macrophage-colony stimulating factor and not tumor progression in patients with lymphoma or myeloma
36. Effect of macrophage- and granulocyte-colony stimulating factors on thymidylate synthase and thymidine kinase activity in rat haematopoietic cells
37. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma
38. A high serum soluble Fad APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma
39. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma
40. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2